MRK Company Profile and Key Details

Q: Who are the executives of MRK?

Lisa LeCointe-CephasSenior Vice President and Chief Ethics & Compliance OfficerMr. Kenneth C. FrazierExecutive ChairmanMs. Cristal N. DowningExecutive Vice President and Chief Communications & Public Affairs OfficerMs. Caroline LitchfieldExecutive Vice President & Chief Financial OfficerMs. Jennifer L. ZacharyExecutive Vice President & Gen. CounselMr. Richard R. DeLuca Jr.Executive Vice President & Pres of Merck Animal HealthMr. Robert M. Davis J.D.Chairman, Pres & Chief Executive OfficerMr. Peter DannenbaumVice President of Investor RelationsMr. Steven C. MizellExecutive Vice President & Chief HR OfficerMr. Chirfi GuindoSenior Vice President & Chief Marketing Officer for Merck Human HealthMr. David Michael WilliamsExecutive Vice President and Chief Information & Digital OfficerDr. Dean Y. Li M.D., Ph.D.Executive Vice President & Pres of Merck Research LaboratoriesMs. Jennifer MauerHead of Global Communications & Corporation Brand

NYSE : MRK

Merck & Co

$120.87

0.03+0.02%

At Close 4:00 PM

74.61

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Merck & Co., Inc. (MRK) stock surged +0.02%, trading at $120.87 on NYSE, up from the previous close of $120.84. The stock opened at $120.56, fluctuating between $119.22 and $121.65 in the recent session.

Stock Snapshot

120.84

Prev. Close

298.84B

Market Cap

119.22

Day Low

16.63

P/E Ratio

7.27

EPS (TTM)

3.61

Cash Flow per Share

120.56

Open

2.47B

Number of Shares

121.65

Day High

99.84%

Free Float in %

14.84

Book Value

6.26M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	120.37	121.65	119.22	120.87	6.25M
Apr 01, 2026	120.88	122.19	120.27	120.84	6.35M
Mar 31, 2026	119.03	121.27	118.77	120.29	10.71M
Mar 30, 2026	120.57	121.64	117.22	118.10	11.04M
Mar 27, 2026	119.29	121.07	118.60	119.63	8.32M
Mar 25, 2026	117.30	120.12	116.80	119.37	10.16M
Mar 24, 2026	114.70	116.54	114.02	116.37	7.41M
Mar 23, 2026	116.17	116.47	114.77	115.68	9.1M
Mar 20, 2026	114.25	115.18	112.72	114.18	36.34M
Mar 19, 2026	114.66	115.76	113.75	114.20	8.38M
Mar 18, 2026	115.06	115.56	113.35	114.50	6.74M
Mar 17, 2026	115.78	116.80	114.38	115.87	7.92M
Mar 16, 2026	115.34	116.06	114.22	115.43	8.78M
Mar 13, 2026	116.92	117.89	115.53	115.61	7.06M
Mar 12, 2026	115.47	116.60	114.30	115.91	8.32M
Mar 11, 2026	116.76	116.95	115.29	116.21	6.76M
Mar 10, 2026	117.24	119.00	116.67	117.09	9.73M
Mar 09, 2026	114.98	117.26	114.11	117.11	8.32M
Mar 06, 2026	115.16	116.36	113.82	115.79	9.4M
Mar 03, 2026	119.67	120.97	118.61	119.83	9.28M

Contact Details

Rahway, NJ 07065

United States

https://www.merck.com 908 740 4000

About Company

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Stock Peers

LLY

-18.9-1.98%

Eli Lilly and Company$935.62 JNJ

-1.08-0.44%

Johnson & Johnson$243.04 ABBV

-6.185-2.88%

AbbVie Inc.$208.80 AZN

2.76+1.37%

AstraZeneca PLC$203.49 NVS

-1.05-0.68%

Novartis AG$154.03 BMY

-2.13-3.45%

Bristol-Myers Squibb Company$59.60 GSK

0.7+1.25%

GSK plc$56.69 NVO

0.495+1.36%

Novo Nordisk A/S$36.98 PFE

-0.22-0.77%

Pfizer Inc.$28.33 OGN

0.22+3.58%

Organon & Co.$6.36

Company Overview

Merck & Co., Inc. (NYSE:MRK) closed at $120.87 USD, gaining $0.03 (0.02%) from the previous close of $120.84. The stock is currently within 5% of its 52-week high $73.31 and $125.14. With a market capitalization of about $298.84 billion, Merck & Co., Inc. is classified as a mega-cap and shows lower-than-market volatility (beta ~0.26). Key stats such as the average daily volume over the past year has been around 11.94 million shares, volume is running light vs its 52-week average. Headquartered in Rahway, NJ, Merck & Co., Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Robert Davis, the company employs approximately 73,000 people and listed since January 13, 1978. Merck & Co., Inc. operates as a healthcare company worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.32%, SMA50 6.92%, SMA200 30.55%). The stock’s 14-day RSI is 56.18 (neutral), while the ATR of 2.88 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -4.63% below its high and over 62.8% above its low. Average 10-day trading volume of 8.61 million shares is below the 3-month average of 11.99 million, indicating normal recent market interest.

Valuation Metrics

Merck & Co., Inc. trades at a P/E ratio of 16.49, slightly below the S&P 500 average, with a price-to-sales ratio of 4.6 and a price-to-book ratio of 5.72 trading at moderately above to book value. The P/FCF stands at 24.18, also above market averages.

Dividend & Fair Value

Merck & Co., Inc. last paid a dividend of 3.32 per share, this equals a trailing yield of roughly 2.38%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $124.19. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

Merck & Co., Inc. generated EPS of $7.28 over the past year. Five-year average earnings growth is 21.23%. Wall Street analysts project EPS growth of 6.27% annually over the next five years. The latest quarter delivered EPS of $2.58. The next quarter is forecast at -$1.54. Next year's EPS is expected at $454.63. Analyst sentiment is neutral. Analyst rating data shows there are 9 Strong Buy ratings, 4 Buy ratings, 13 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $150.00 to $90.00. The high target offers 24.1% upside. The low target suggests -25.54% downside. The mean target is $120.19. This offers -0.56% upside. Merck & Co., Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 9.32%. The prior quarter beat by 4.93%. Over the last six quarters, Apple has recorded several small beats. These include 5.56% in July 30, 2024.

Shareholding & Insider Activity

Merck & Co., Inc. has 2.47 billion shares outstanding. The public float is 2.47 billion shares, elevated short interest at 1.26% of float. This equals 28.13 million shares. The short ratio is 2.03 days. Institutional investors hold 80.64% of the float. Insiders own 0.07%. FRAZIER KENNETH C holds 700.65 thousand shares, Davis Robert M has 443.60 thousand shares and DeLuca Richard R. has 160.17 thousand shares. Over the past six months, insider transactions show net selling. They sold 254.40 thousand shares across 14 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Merck & Co generated $59.87B in revenue, or $23.51 per share. Gross margin was 73.31%, operating margin 4.98%, and net profit margin 0.61%. Returns are modest, with ROA at 0.34% and ROE at 0.97%.
On valuation metrics, Merck & Co trades at a P/E of 16.49, P/S of 4.60 and P/B of 5.72. The current ratio is 1.54 and quick ratio is 1.30. Operationally, the company’s inventory turnover is 1.81 and cash conversion cycle is 139.59 days. Debt-to-equity is 0.96, supported by a cash flow-to-debt ratio of 0.33.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Merck & Co posted revenue of $59.87B, down slightly from $59.28B in the prior quarter. Gross profit was $43.89B (margin 73.31%). Operating income was $2.98B (margin 5.0%). Net income was$365.00M (EPS $0.14).
The company ended the quarter with $7.16B in cash and short-term investments, a total debt of $36.27B, and net debt of $29.36B. Total assets were $106.68B, with equity of $37.64B. Financials further reflected stability, with operating cash flow of $13.01B, free cash flow of $9.14B, and capital expenditures of - $3.86B.

Price Forecast & Outlook

Our AI price prediction model suggests that Merck & Co., Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.45%, with price expected at $126.25 by April 16, 2026, within a range of $123.39 to $129.04 3-Month Outlook: Projected rise of 68.26%, reaching $203.38 by July 01, 2026, with a range of $200.72 to $206.73. 1-Year Outlook: Projected loss of -4.02%, with price at $116.01 by April 02, 2027, within a range of $111.62 to $121.90.

Key Takeaways

Merck & Co., Inc. (NYSE:MRK) shares are flat 3.98% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Merck & Co., Inc. trading at a premium to the broader market with a P/E of 16.49. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $118.67, suggesting -1.82% downside. Our AI forecast model points to short-term strength (4.45% over two weeks), a medium-term rise (68.26% over three months), and a longer-term loss (-4.02% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Merck & Co., Inc. (MRK) stock price?

Merck & Co., Inc. (NYSE: MRK) stock price is $120.87 in the last trading session. During the trading session, MRK stock reached the peak price of $121.65 while $119.22 was the lowest point it dropped to. The percentage change in MRK stock occurred in the recent session was 0.02% while the dollar amount for the price change in MRK stock was $0.03.

MRK's industry and sector of operation?

The NYSE listed MRK is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Merck & Co., Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MRK?

Lisa LeCointe-Cephas
Senior Vice President and Chief Ethics & Compliance Officer
Mr. Kenneth C. Frazier
Executive Chairman
Ms. Cristal N. Downing
Executive Vice President and Chief Communications & Public Affairs Officer
Ms. Caroline Litchfield
Executive Vice President & Chief Financial Officer
Ms. Jennifer L. Zachary
Executive Vice President & Gen. Counsel
Mr. Richard R. DeLuca Jr.
Executive Vice President & Pres of Merck Animal Health
Mr. Robert M. Davis J.D.
Chairman, Pres & Chief Executive Officer
Mr. Peter Dannenbaum
Vice President of Investor Relations
Mr. Steven C. Mizell
Executive Vice President & Chief HR Officer
Mr. Chirfi Guindo
Senior Vice President & Chief Marketing Officer for Merck Human Health
Mr. David Michael Williams
Executive Vice President and Chief Information & Digital Officer
Dr. Dean Y. Li M.D., Ph.D.
Executive Vice President & Pres of Merck Research Laboratories
Ms. Jennifer Mauer
Head of Global Communications & Corporation Brand

How MRK did perform over past 52-week?

MRK's closing price is 64.88% higher than its 52-week low of $73.31 where as its distance from 52-week high of $125.14 is -3.41%.

How many employees does MRK have?

Number of MRK employees currently stands at 73,000.

Link for MRK official website?

Official Website of MRK is: https://www.merck.com

How do I contact MRK?

MRK could be contacted at phone 908 740 4000 and can also be accessed through its website. MRK operates from 126 East Lincoln Avenue, Rahway, NJ 07065, United States.

How many shares of MRK are traded daily?

MRK stock volume for the day was 6.26M shares. The average number of MRK shares traded daily for last 3 months was 11.94M.

What is the market cap of MRK currently?

The market value of MRK currently stands at $298.84B with its latest stock price at $120.87 and 2.47B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	73000
Beta	0.26
Sales or Revenue	$59.87B
5Y Sales Change%	0.413%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

MRK Company Profile and Key Details

Merck & Co

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Key Takeaways

Dividend & Fair Value

Price Forecast & Outlook

Company Overview

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics